Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,396 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Interstitial Nephritis
Interventions
Omalizumab, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
DCDT2980S, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Conditions
Small Cell Lung Cancer
Interventions
Trilaciclib, Placebo, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
732 participants
Timeline
2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
45
States / cities
Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
Conditions
Mesothelioma
Interventions
Carboplatin, Bevacizumab and Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Breast Cancer
Interventions
bevacizumab, cyclophosphamide, methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Alzheimer's Disease
Interventions
Placebo, RO7105705
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Non-small Cell Lung Cancer
Interventions
Atezolizumab and Interleukin-12 Gene Therapy
Combination Product
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Neoplasms
Interventions
Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pancreatic Cancer
Interventions
Erlotinib, gemcitabine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Conditions
Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Interventions
Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone
Drug
Lead sponsor
Heather Wakelee
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
4
States / cities
Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more
Conditions
Metastatic Breast Cancer
Interventions
paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Conditions
Sinusitis
Interventions
Anti-IgE antibody omalizumab or placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lung Cancer
Interventions
Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Denver, Colorado
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Conditions
Lymphoma
Interventions
Rituximab, GM-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
182
States / cities
Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
Conditions
Non Small Cell Lung Cancer
Interventions
erlotinib, sunitinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • La Verne, California • Athens, Georgia + 8 more
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania